Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 5/20 | 0.54 |
| ▸ | MDM4 | O15151 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.49 |
| ▸ | CASP3 | P42574 | 2/20 | 0.47 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29400931 | 1.00 | MDM2 (0.54) | MDM2MDM4TP53PTPN1CASP3 | |
| SCHEMBL29908133 | 1.00 | MDM2 (0.54) | MDM2MDM4TP53PTPN1CASP3 | |
| SCHEMBL120627 | 1.00 | MDM2 (0.54) | MDM2MDM4TP53PTPN1CASP3 | |
| SCHEMBL29445603 | 1.00 | MDM2 (0.54) | MDM2MDM4TP53PTPN1CASP3 | |
| SCHEMBL119539 | 1.00 | MDM2 (0.54) | MDM2MDM4TP53PTPN1CASP3 | |
| SCHEMBL25360926 | 0.92 | MDM2 (0.56) | MDM2MDM4TP53PTPN1CASP3 | |
| SCHEMBL15083325 | 0.92 | MDM2 (0.52) | MDM2MDM4TP53PTPN1CASP3 | |
| SCHEMBL30898982 | 0.92 | MDM2 (0.52) | MDM2MDM4TP53PTPN1CASP3 | |
| SCHEMBL25360931 | 0.92 | MDM2 (0.56) | MDM2MDM4TP53PTPN1CASP3 | |
| SCHEMBL16287905 | 0.92 | MDM2 (0.52) | MDM2MDM4TP53PTPN1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325508-A1 | MODULATORS OF PROTEASOME DYNAMICS AND/OR FUNCTION, COMPOSITIONS, METHODS, AND THERAPEUTIC USES THEREOF | TECHNION RES & DEV FOUNDATION (IL) | 2025-10-23 | — | — | US | disclosed |
| US-12123018-B2 | Self-assembled hybrid hydrogels formed of a short aromatic peptide and an aromatic amino acid | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2024-10-22 | — | — | US | disclosed |
| US-20230330064-A1 | TYROSINE, TRYPTOPHAN AND PHENYLALANINE AS mTOR AGONISTS MEDIATING PROTEASOME DYNAMICS, COMPOSITIONS, METHODS AND USES THEREOF IN THERAPY, AND PROGNOSTIC METHODS FOR DRUG-RESISTANCE | RAMBAM MED-TECH LTD. (IL) | 2023-10-19 | — | — | US | disclosed |
| CN-115053184-A | Composition for forming EUV resist underlayer film | 日产化学株式会社 | 2022-09-13 | — | — | CN | disclosed |
| CN-109134481-B | Substituted pyrrole chromone compound or pharmaceutically acceptable salt thereof, and preparation method and application thereof | 中山大学 | 2021-05-14 | — | — | CN | disclosed |
| US-20200165565-A1 | SELF-ASSEMBLED HYBRID HYDROGELS FORMED OF A SHORT AROMATIC PEPTIDE AND AN AROMATIC AMINO ACID | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2020-05-28 | — | — | US | disclosed |
| EP-3652194-A1 | SELF-ASSEMBLED HYBRID HYDROGELS FORMED OF A SHORT AROMATIC PEPTIDE AND AN AROMATIC AMINO ACID | Ramot at Tel-Aviv University Ltd. (IL) | 2020-05-20 | — | — | EP | disclosed |
| EP-2970390-B1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL MYERS SQUIBB CO (US) | 2019-11-06 | — | — | EP | disclosed |
| WO-2019012545-A1 | SELF-ASSEMBLED HYBRID HYDROGELS FORMED OF A SHORT AROMATIC PEPTIDE AND AN AROMATIC AMINO ACID | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2019-01-17 | — | — | WO | disclosed |
| US-9879046-B2 | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-30 | — | — | US | disclosed |
| US-20160158349-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL MYERS SQUIBB CO (US) | 2016-06-09 | — | — | US | disclosed |
| US-9308236-B2 | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-04-12 | — | — | US | disclosed |
| EP-2970390-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | Bristol-Myers Squibb Company (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20140294898-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL-MYERS SQUIBB COMPANY | 2014-10-02 | — | — | US | disclosed |
| WO-2014151634-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-25 | — | — | WO | disclosed |
| US-8338565-B2 | Macrocyclic compounds for inhibition of tumor necrosis factor alpha | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2012-12-25 | — | — | US | disclosed |
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | ENSEMBLE THERAPEUTICS CORPORATION | 2010-06-17 | — | — | US | disclosed |
| US-20090215783-A1 | COMPOSITION FOR INDUCTION OR INHIBITION OF STEM CELL DIFFERENTIATION | CHOONGWAE PHARMA CORPORATION (KR) | 2009-08-27 | — | — | US | disclosed |
| EP-2029142-A1 | COMPOSITION FOR INDUCTION OR INHIBITION OF STEM CELL DIFFERENTIATION | Choongwae Pharma Corporation (KR) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007139346-A1 | COMPOSITION FOR INDUCTION OR INHIBITION OF STEM CELL DIFFERENTIATION | CHOONGWAE PHARMA CORPORATION (KR) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330064-A1 | TYROSINE, TRYPTOPHAN AND PHENYLALANINE AS mTOR AGONISTS MEDIATING PROTEASOME DYNAMICS, COMPOSITIONS, METHODS AND USES THEREOF IN THERAPY, AND PROGNOSTIC METHODS FOR DRUG-RESISTANCE | RPTOR, PSMG3, MTOR | MDM2 86/4885MDM4 1267/4885TP53 106/4885 |
| US-20250325508-A1 | MODULATORS OF PROTEASOME DYNAMICS AND/OR FUNCTION, COMPOSITIONS, METHODS, AND THERAPEUTIC USES THEREOF | PSMC1, PSME3, PSMA6 | MDM2 161/4885MDM4 1440/4885TP53 595/4885 |
| US-20090215783-A1 | COMPOSITION FOR INDUCTION OR INHIBITION OF STEM CELL DIFFERENTIATION | MYLK2, TNNC1, MYH2 | MDM2 1756/4885MDM4 927/4885TP53 2387/4885 |
| US-20140294898-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | CD274, PDCD1, PDCD1LG2 | MDM2 768/4885MDM4 550/4885TP53 100/4885 |
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | TNF, CD40, TNFRSF1A | MDM2 1236/4885MDM4 1060/4885TP53 573/4885 |
| US-20160158349-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | CD274, PDCD1, PDCD1LG2 | MDM2 768/4885MDM4 550/4885TP53 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.